coronary artery disease
Biobanks have been making strides in gathering data from more diverse populations this year while the evidence for the clinical utility of embryo PRS testing remains insufficient.
The Finnish diagnostics company is working to expand US and European sales of its ceramide lipid-based cardiovascular risk assessment assay, CERT.
The company is collecting validation evidence it intends to submit to the FDA next year, which will also support launch of the test as an LDT.
The company has been focused on commercializing its technology for heart attack assessment, but the new data shows how it could be used for CAD risk, as well.
Polygenic SNP Score Correlates With Early-Onset Coronary Artery Disease Risk
Investigators came up with a 182-variant risk score for early-onset coronary artery disease, which they tested on SNP data from UK Biobank participants with or without the condition.